Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers
Press
This is some text inside of a div block.
April 5, 2024
Related announcements
Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform
Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform
Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
Iambic Therapeutics to Present New Pre-Clinical Data for IAM1363, a Selective and Brain-Penetrant Inhibitor of both HER2 Wild-Type and Oncogenic Mutants, at the 2024 AACR Annual Meeting
Iambic Therapeutics Announces First Patient Dosed in Phase 1 Clinical Study of IAM1363, a Highly Selective HER2 Inhibitor for the Treatment of Solid Tumors